Induction with basiliximab in renal transplantation.
Ferrer
F
F
Renal Transplantation Unit, Hospitais da Universidade de Coimbra, Coimbra, Portugal. franciscodina@gmail.com
Machado
S
S
Alves
R
R
Macário
F
F
Bastos
C
C
Roseiro
A
A
Mota
A
A
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D019138:Antibodies, Blocking / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival / Q000187:drug effects; D006680:HLA Antigens / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012189:Retrospective Studies; D015996:Survival Rate
D000305:Adrenal Cortex Hormones; D019138:Antibodies, Blocking; D000911:Antibodies, Monoclonal; D006680:HLA Antigens; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D000077552:Basiliximab; D003404:Creatinine; D009173:Mycophenolic Acid